for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Oxford will study top-selling prescription drug for potential COVID-19 treatment

LONDON, Sept 30 (Reuters) - Britain’s Oxford University said on Wednesday it would study whether the world’s best-selling prescription medicine, adalimumab, was an effective treatment for COVID-19 patients, the latest effort to repurpose existing drugs as potential coronavirus therapies.

The AVID-CC trial will test the anti-tumour necrosis factor (anti-TNF) drug and will be aimed at treating people in the community, especially in care homes. It will enrol up to 750 patients from community care settings throughout the UK.

Reporting by Josephine Mason and Kate Kelland Editing by Gareth Jones

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up